Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone

Clinical Trial

J Snigurowicz et al. Arch Immunol Ther Exp (Warsz). 1981.

. 1981;29(2):145-53.

No abstract available

Similar articles

Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U, Crivellari D, Carbone A, Veronesi A, Galligioni E, Trovò MG, Tumolo S, Grigoletto E. Tirelli U, et al. Cancer Treat Rep. 1982 Nov;66(11):1971-3. Cancer Treat Rep. 1982. PMID: 6897205
Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Abramson N, Lurie P, Mietlowski WL, Schilling A, Bennett JM, Horton J. Abramson N, et al. Cancer Treat Rep. 1982 Jun;66(6):1273-7. Cancer Treat Rep. 1982. PMID: 7044535 Clinical Trial.
Multiple myeloma: results with the M-2 protocol in a community hospital.
Miller S, Perrotta AL. Miller S, et al. J Am Osteopath Assoc. 1979 Aug;78(12):857-64. J Am Osteopath Assoc. 1979. PMID: 489428 No abstract available.
Current concepts in cancer. Multiple myeloma.
McIntyre OR. McIntyre OR. N Engl J Med. 1979 Jul 26;301(4):193-6. doi: 10.1056/NEJM197907263010405. N Engl J Med. 1979. PMID: 377077 Review. No abstract available.
[Chemotherapy of multiple myeloma].
Golenkov AK. Golenkov AK. Sov Med. 1991;(3):43-6. Sov Med. 1991. PMID: 1882290 Review. Russian. No abstract available.